These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 27211090)

  • 81. Reply to comments on "State of the art in magnetic resonance imaging of hepatocellular carcinoma": the role of DWI.
    Horvat N; Monti S; Oliveira BC; Rocha CCT; Giancipoli RG; Mannelli L
    Radiol Oncol; 2019 Jul; 53(3):371-372. PubMed ID: 31314741
    [No Abstract]   [Full Text] [Related]  

  • 82. Meta-analysis of the accuracy of Liver Imaging Reporting and Data System category 4 or 5 for diagnosing hepatocellular carcinoma.
    Kim DH; Choi SH; Park SH; Kim KW; Byun JH; Kim SY; Lee SS; Shin YM; Won HJ; Kim PN
    Gut; 2019 Sep; 68(9):1719-1721. PubMed ID: 31300516
    [No Abstract]   [Full Text] [Related]  

  • 83. [Imaging diagnosis and molecular profiling of hepatocellular carcinoma].
    Yasui Y; Kurosaki M; Izumi N
    Nihon Shokakibyo Gakkai Zasshi; 2016 May; 113(5):785-9. PubMed ID: 27151474
    [No Abstract]   [Full Text] [Related]  

  • 84. [Early diagnosis of hepatocellular carcinoma].
    Mao Y; Xu H
    Zhonghua Nei Ke Za Zhi; 2014 Jul; 53(7):508-10. PubMed ID: 25264001
    [No Abstract]   [Full Text] [Related]  

  • 85. Is It Time to Expand the Definition of Washout Appearance in LI-RADS?
    Fowler KJ; Sirlin CB
    Radiology; 2019 Jun; 291(3):658-659. PubMed ID: 30990765
    [No Abstract]   [Full Text] [Related]  

  • 86. Methylcellulose as a rectal contrast agent for MR imaging of rectal carcinoma.
    Goh JS; Goh JP; Wansaicheong GK
    AJR Am J Roentgenol; 2002 May; 178(5):1145-6. PubMed ID: 11959719
    [No Abstract]   [Full Text] [Related]  

  • 87. [8. Polymeric MR Contrast Agents for Microvascular Imaging].
    Mahara A
    Nihon Hoshasen Gijutsu Gakkai Zasshi; 2022; 78(5):520-525. PubMed ID: 35598961
    [No Abstract]   [Full Text] [Related]  

  • 88. Editorial Comment: Is It Time to Focus on LR-M?
    Magnetta MJ
    AJR Am J Roentgenol; 2022 Sep; 219(3):433. PubMed ID: 35383489
    [No Abstract]   [Full Text] [Related]  

  • 89. C-reactive protein, a prognostic marker in hepatocellular carcinoma.
    Dufour JF
    Hepatology; 2013 Jun; 57(6):2103-5. PubMed ID: 23315964
    [No Abstract]   [Full Text] [Related]  

  • 90. Why do not widen the use of Acoustic Radial Force Impulse method to staging assessment of the retroperitoneal fibrosis?
    Alberti C
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17(4):566. PubMed ID: 23467960
    [No Abstract]   [Full Text] [Related]  

  • 91. Magnetic resonance imaging of liver tumors.
    Lencioni R; Cioni D; Crocetti L; Della Pina C; Bartolozzi C
    J Hepatol; 2004 Jan; 40(1):162-71. PubMed ID: 14672629
    [No Abstract]   [Full Text] [Related]  

  • 92. The Feasibility of Abbreviated MRI for Active Surveillance of Hepatocellular Carcinoma.
    Kim H
    Radiology; 2023 Apr; 307(2):e223113. PubMed ID: 36692405
    [No Abstract]   [Full Text] [Related]  

  • 93. Metabolic disease as a risk of hepatocellular carcinoma.
    Nishida N
    Clin Mol Hepatol; 2021 Jan; 27(1):87-90. PubMed ID: 33317238
    [No Abstract]   [Full Text] [Related]  

  • 94. New assay for early detection of hepatocellular carcinoma.
    Cancer; 2022 Dec; 128(24):4176. PubMed ID: 36445105
    [No Abstract]   [Full Text] [Related]  

  • 95. An Unusual Extrahepatic Hepatocellular Carcinoma.
    Jacob R; Kasim Ismail A; Prakoso E
    Clin Gastroenterol Hepatol; 2021 Dec; 19(12):e123-e124. PubMed ID: 32668340
    [No Abstract]   [Full Text] [Related]  

  • 96. [Liver cancer: progress in diagnosis and treatments. Topics: V. Progress in diagnosis of liver cancer; 3. MR imaging of the liver cancer].
    Akahane M
    Nihon Naika Gakkai Zasshi; 2014 Jan; 103(1):61-9. PubMed ID: 24605492
    [No Abstract]   [Full Text] [Related]  

  • 97. Augmented liver pathology: artificial intelligence and the assessment of hepatocellular neoplasms.
    Burt AD
    Histopathology; 2023 Oct; 83(4):509-511. PubMed ID: 37698049
    [No Abstract]   [Full Text] [Related]  

  • 98. Time to Clarify Common Misconceptions about the Liver Imaging Reporting and Data System for Contrast-enhanced US.
    Kono Y; Sirlin CB; Fetzer DT; Kim TK; Rodgers SK; Piscaglia F; Lyshchik A; Dietrich CF; Wilson SR
    Radiology; 2020 Apr; 295(1):245-247. PubMed ID: 32068508
    [No Abstract]   [Full Text] [Related]  

  • 99. The challenges of novel contrast agents for the imaging diagnosis of hepatocellular carcinoma.
    Ayuso C; Bruix J
    Hepatol Int; 2014 Jan; 8(1):4-6. PubMed ID: 26202400
    [No Abstract]   [Full Text] [Related]  

  • 100. Imaging Techniques for Hepatocellular Carcinoma.
    Sirlin C
    Gastroenterol Hepatol (N Y); 2015 Jun; 11(6):403-5. PubMed ID: 27118935
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.